Daehan New Pharm Co., Ltd. (KOSDAQ: 054670)
South Korea
· Delayed Price · Currency is KRW 8,230.00
+10.00 (0.12%)
Oct 11, 2024, 9:00 AM KST
Daehan New Pharm Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2012 | FY 2011 | FY 2010 | FY 2009 | FY 2008 | 2007 - 2005 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '13 Sep 30, 2013 | Dec '12 Dec 31, 2012 | Dec '11 Dec 31, 2011 | Dec '10 Dec 31, 2010 | Dec '09 Dec 31, 2009 | Dec '08 Dec 31, 2008 | 2007 - 2005 |
| Revenue | 54,475 | 48,010 | 44,523 | 49,647 | 40,403 | 33,979 | Upgrade
|
| Revenue Growth (YoY) | 19.23% | 7.83% | -10.32% | 22.88% | 18.91% | -36.82% | Upgrade
|
| Cost of Revenue | 24,566 | 23,337 | 21,286 | 25,212 | 21,933 | 21,198 | Upgrade
|
| Gross Profit | 29,909 | 24,674 | 23,237 | 24,436 | 18,470 | 12,781 | Upgrade
|
| Selling, General & Admin | 25,568 | 21,222 | 17,880 | 17,910 | 12,000 | 11,688 | Upgrade
|
| Research & Development | - | - | - | 856.6 | 127.78 | 233.52 | Upgrade
|
| Other Operating Expenses | - | - | - | 342.26 | 311.87 | 424.55 | Upgrade
|
| Operating Expenses | 25,568 | 21,222 | 17,880 | 19,872 | 14,229 | 12,721 | Upgrade
|
| Operating Income | 4,341 | 3,451 | 5,358 | 4,564 | 4,241 | 60.11 | Upgrade
|
| Interest Expense | -3,735 | -3,389 | -3,074 | -2,090 | -1,743 | -2,340 | Upgrade
|
| Interest & Investment Income | 345.89 | 214.5 | 173.25 | 197.93 | 1,809 | 102.78 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | - | -545.56 | -2,189 | 9,994 | Upgrade
|
| Other Non Operating Income (Expenses) | -4,400 | -5,740 | -1,524 | -5,448 | 193.33 | -458.51 | Upgrade
|
| EBT Excluding Unusual Items | -3,448 | -5,463 | 932.95 | -3,323 | 2,311 | 7,358 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | 0.81 | 38.8 | 2.29 | Upgrade
|
| Pretax Income | -3,448 | -5,463 | 932.95 | -3,322 | 2,350 | 7,360 | Upgrade
|
| Income Tax Expense | 556.28 | 65.93 | 289.4 | -550.72 | 734.75 | 1,648 | Upgrade
|
| Earnings From Continuing Operations | -4,005 | -5,529 | 643.55 | -2,771 | 1,615 | 5,712 | Upgrade
|
| Earnings From Discontinued Operations | - | - | - | - | -1,255 | 36.74 | Upgrade
|
| Net Income | -4,005 | -5,529 | 643.55 | -2,771 | 360.71 | 5,748 | Upgrade
|
| Net Income to Common | -4,005 | -5,529 | 643.55 | -2,771 | 360.71 | 5,748 | Upgrade
|
| Net Income Growth | - | - | - | - | -93.72% | 761.85% | Upgrade
|
| Shares Outstanding (Basic) | 14 | 13 | 13 | 13 | 13 | 13 | Upgrade
|
| Shares Outstanding (Diluted) | 14 | 13 | 13 | 13 | 13 | 13 | Upgrade
|
| Shares Change (YoY) | 6.45% | -0.24% | -2.36% | -0.07% | 3.67% | 20.86% | Upgrade
|
| EPS (Basic) | -285.93 | -422.00 | 49.00 | -206.36 | 26.86 | 445.94 | Upgrade
|
| EPS (Diluted) | -285.93 | -422.00 | 49.00 | -206.36 | 26.80 | 444.32 | Upgrade
|
| EPS Growth | - | - | - | - | -93.97% | 616.64% | Upgrade
|
| Free Cash Flow | -765.05 | -983.18 | 2,213 | -11,287 | -4,301 | 4,029 | Upgrade
|
| Free Cash Flow Per Share | -54.62 | -75.04 | 168.48 | -839.11 | -319.53 | 310.32 | Upgrade
|
| Gross Margin | 54.90% | 51.39% | 52.19% | 49.22% | 45.71% | 37.61% | Upgrade
|
| Operating Margin | 7.97% | 7.19% | 12.03% | 9.19% | 10.50% | 0.18% | Upgrade
|
| Profit Margin | -7.35% | -11.52% | 1.45% | -5.58% | 0.89% | 16.92% | Upgrade
|
| Free Cash Flow Margin | -1.40% | -2.05% | 4.97% | -22.73% | -10.65% | 11.86% | Upgrade
|
| EBITDA | 5,931 | 4,861 | 6,129 | 5,176 | 4,689 | 565 | Upgrade
|
| EBITDA Margin | 10.89% | 10.12% | 13.77% | 10.42% | 11.61% | 1.66% | Upgrade
|
| D&A For EBITDA | 1,590 | 1,410 | 771.14 | 611.97 | 448.13 | 504.9 | Upgrade
|
| EBIT | 4,341 | 3,451 | 5,358 | 4,564 | 4,241 | 60.11 | Upgrade
|
| EBIT Margin | 7.97% | 7.19% | 12.03% | 9.19% | 10.50% | 0.18% | Upgrade
|
| Effective Tax Rate | - | - | 31.02% | - | 31.27% | 22.40% | Upgrade
|
| Revenue as Reported | - | - | - | 49,647 | 40,403 | 33,979 | Upgrade
|
| Advertising Expenses | - | - | - | 1,687 | 1,363 | 1,124 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.